19th Annual European Life Sciences CEO Forum

Sepsis remains one of the most urgent and costly medical challenges worldwide, with a critical need for innovative therapies. ARTCLINE is pioneering a novel allogeneic immune cell-based extracorporeal therapy for the treatment of septic shock, ARTICE®, designed to restore immune function and significantly improve patient outcomes. ARTICE® is the only therapy that targets both the early hyperinflammatory phase and the late immunoparalysis phase, addressing the root cause of sepsis immune dysfunction. By combining advanced immune cell modulation with an innovative plasma perfusion system, ARTICE® not only reduces inflammation and mortality but improves immune function and expedites long-term patient recovery. Unlike current treatments that focus on infection or inflammation alone, ARTICE® offers a comprehensive, personalized approach, resulting in superior clinical outcome. ARTCLINE has developed its patented ARTICE® Therapy to market readiness and regulatory approvals have been obtained already. A final clinical validation is currently being conducted in a multicenter study in Germany to evaluate the effectiveness of ARTICE®. A broad market launch is expected to take place in the second half of 2026, opening a new therapeutic window in sepsis treatment – in an area where options have been limited so far.

Biocytogen is a global biotech company that drives the discovery of fully human monoclonal, bispecific, multispecific, ADC, VHH, and TCR-mimic antibodies across 1,000+ druggable targets, providing 1M+ authentic antibody sequences through its RenBiologics™ sub-brand for partnerships. Biocytogen is advancing antibody drug development through innovative technologies. Leveraging gene-editing expertise, it pioneered drug target knock-in humanized models and offers 4,000+ models via BioMice™, along with in vivo, ex vivo, and in vitro pharmacology and custom gene-editing services.

BioTalent | Talent Science™ Recruitment & Predictive Workforce Engineering for Biopharma Workforce volatility is one of the most significant unmanaged risks in biopharma, quietly costing manufacturing sites £5–15M annually, while 89% of executives are unable to quantify its impact. The most expensive and volatile asset on the balance sheet, talent, often remains unmeasured and unmanaged with the same precision applied to equipment, supply chains, or intellectual property. Critical shortages across automation, QA/QC, digital, AI and advanced manufacturing capabilities now affect approximately 70% of firms. Traditional HR metrics describe headcount, attrition, and hiring lag, yet they do not predict execution risk, measure workforce drag, or demonstrate return on investment. Evidence consistently shows that workforce performance drives up to 23% of EBITDA variance in complex operations. Despite this, most leadership teams lack predictive visibility into where execution risk will emerge next. Our Approach BioTalent combines specialist recruitment expertise with Talent Science™, a quantitative workforce modelling platform designed specifically for biopharma. Talent Science™ treats the workforce as a performance system. Using predictive analytics, complexity modelling, and risk quantification frameworks such as Talent Efficiency (TE), the Biopharma Talent Index (BTI), and Workforce Value-at-Risk (WVaR), we measure and optimise capability alignment, decision flow, succession depth, volatility exposure, and transformation readiness. This enables leadership teams to: Quantify workforce-driven execution risk Prioritise high-impact hires rather than reactive hiring Reduce dependency on critical individuals Align digital and automation strategy with capability readiness Engineer workforce stability as portfolio complexity increases Recruitment is then deployed with precision Measurable Outcomes 15–25% uplift in automation and digital transformation ROI $5–15M annual risk reduction through volatility management 2–5% EBITDA improvement within 12–18 months What Makes BioTalent Different We combine sector-leading biopharma recruitment capability with predictive workforce engineering, linking talent decisions directly to operational throughput, risk reduction, and enterprise value.

Intelligencia AI is a technology company that develops artificial intelligence (AI) and software solutions designed to de-risk and streamline the drug development process. Founded in 2017, the company uses machine learning and curated data to estimate the probability of success (PoS) for clinical trials, helping pharmaceutical and biotechnology companies make better decisions and reduce the high costs and long timelines associated with drug development.

iOmx is a clinical-stage biotech company that harnesses deep tumor immunology insights to generate novel breakthrough I/O therapeutics for the most prevalent solid tumor indications. The company is translating unexplored immune evasion biology into a growing pipeline of multi-functional powerful biologics with single-agent activity that overcome resistance in major solid tumors. By applying its comprehensive drug discovery & development expertise, iOmx is committed to shaping the future of cancer therapy. iOmx is backed by international venture capital investors, such as ATHOS, Sofinnova Partners, Wellington Partners, MIG Capital, M Ventures as well as Arvantis. iOmx was founded in 2016 and is based in Munich.

Nimvec Therapeutics has developed a groundbreaking non-immunogenic repeated dose-enabling viral platform to deliver any transgene of choice into humans. It is advancing a pipeline of transformative, potentially curative gene therapies for a range of rare and prevalent diseases, including monogenetic indications, autoimmune diseases and chronic inflammation. Nimvec™ AM510 is a tolerance inducing gene therapy for the treatment of Type 1 Diabetes. Diabetes is an autoimmune disease where self-reactive T lymphocytes selectively attack and destroy insulin-producing β cells lodged within the pancreas, leaving the patient unable to maintain glucose homeostasis. Proinsulin (PI) is considered to be the primary self-antigen involved in the autoimmune β cell destruction. To date, Type 1 Diabetes cannot be cured and the glucose homeostasis can be more or less maintained in patients by daily insulin injections. Although Diabetes is seen as a manageable disease nowadays, secondary complications of the current therapy are considerable and lead to significant morbidity and mortality. Using Nimvec™ AM510 we intend to restore the immune tolerance to proinsulin and potentially cure the patients.

Optigo Biotherapeutics an opthalmology biotech company disrupting the multi-billion dollar retina market. Optigo has developed a proprietary anchor domain that can enhance 1/2 life of biologics by 10X. Company’s lead asset, XPK-640, is a bifunctional fusion protein based on aflibercept that leverages a proprietary Vitreous Anchor platform. By binding to endogenous hyaluronic acid, it extends drug half-life 10-fold, enabling a once-yearly injection—a paradigm shift from monthly standards. With broad modularity for all retinal biologics and approximately 15 months from IND, Optigo offers a scalable solution to the industry’s greatest challenge: treatment burden. Two addtional assets in the pipeline that target GA and DME.

Rejuvenate Biomed is a clinical-stage, AI-enabled biopharma company developing oral combination therapies for age-related diseases. Its lead asset, RJx-01, has shown strong safety and clinical efficacy in human sarcopenia studies with a disease-modifying mechanism of action. Phase 2b readouts are expected in 2026 and 2027. Powered by the proprietary CombinAge® (AI) and CelegAge® (in vitro) platforms, the company is building a broader aging pipeline. Rejuvenate Biomed is actively seeking strategic partnerships for RJx-01, as well as platform and pipeline collaboration. Further, Rejuvenate Biomed is raising a Series C to advance RJx-01, bring RJx-03 and RJx-07 into the clinic, and scale its discovery platforms.

Ryvu Therapeutics is a clinical-stage drug discovery and development company focused on novel oncology therapies that address emerging targets in oncology. Ryvu’s pipeline includes a first-in-class CDK8/19 inhibitor romaciclib (RVU120, SEL120) , with encouraging signs of efficacy in Phase II across heme malignancies, and a broad pipeline of novel precision medicine, synthetic lethality and ADC payload assets. Ryvu’s most advanced program is romaciclib (RVU120, SEL120) , a selective CDK8/CDK19 kinase inhibitor with broad potential in hematological malignancies. RVU120 is currently in Phase II development (i) in combination with venetoclax for the treatment of patients with r/r AML – the RIVER-81 study, (ii) as a monotherapy for the treatment of patients with lower-risk myelodysplastic syndromes (LR-MDS) – the REMARK study, (iii) as a monotherapy and in combination with ruxolitinib for the treatment of patients with myelofibrosis (MF) – the POTAMI-61 study. RVU305, a potentially best-in-class, brain-permeable PRMT5 inhibitor to treat multiple solid tumors, is currently in IND/CTA-enabling studies. Ryvu is also pursuing novel precision oncology and synthetic lethality targets through its ONCO Prime platform, which uses patient-derived cells to discover innovative targets across a variety of tumor types. In addition, Ryvu is developing several novel ADC payloads, building on its experience with STING-based ADCs that are being developed in collaboration with Exelixis. Ryvu also has key collaborations with Menarini and BioNTech. Dapolsertib (MEN1703, SEL24) is a dual PIM/FLT3 kinase inhibitor licensed to the Menarini Group that is currently being investigated in a Phase II study in diffuse large B-cell lymphoma (DLBCL) – the JASPIS-01 study. With BioNTech, Ryvu has a target-based drug discovery collaboration in immuno-oncology. Ryvu was founded in 2007 and is headquartered in Kraków, Poland. It is listed on the Warsaw Stock Exchange and is a component of the sWIG80 index.

TAXIS develops drugs to kill deadly infectious diseases. Our current focus is on AMR (antimicrobial resistant bacteria). For more than 30yrs, all new antibiotics have been incremental innovations on old themes - 'generation X' drugs, where there is pre-existing resistance that limits their clinical utility. At TAXIS, we aim for transformational innovation and our approach has lead to the discovery and development of 3 new classes of antimicrobials - each with its own novel mechanism of action. We have one new antimicrobial, an oral anti-MRSA agent, that completed Phase I (FIH) study and is prepared to move forward into Phase II. TAXIS has 2 other unique technologies in preclinical, both backed by by large, active NIH grants. Our technologies target 7 of the CDC's top 10 Priority Pathogens.

Abalos is a clinical stage company developing a transformative approach to overcome cancer immunotherapy hurdles and break down solid tumors. Abalos is preparing for the next financing round to expand clinical trials with our lead product ABX-001 and to broaden our product pipeline. Abalos offers a unique investment opportunity with multiple milestones in the next 12 months, including early clinical validation of our technology and expansion of our pipeline. After a single i.v. administration, our products induce exceptional levels of effector t-cells and actively guide these and other immune cells into the primary tumor and distant metastases. Furthermore, our technology creates an inflamed tumor environment, which results in further boosting of anti-tumor activity. We achieve this by leveraging and optimizing the well-described properties of arenaviruses as a platform for replicating (non-oncolytic) viro-therapeutics for systemic use. Our lead product ABX-001 is in clinical testing. It has shown strong efficacy in pre-clinical studies against a broad range of tumors and has a very clean pre-clinical safety profile, including excellent safety at high doses in non-human primate studies. A robust and scalable cGMP manufacturing process has been established. Clinical trials with ABX-001 started in Q4 2025, with interim results expected in Q2 of this year. Based on its unique mechanism of action, ABX-011 has potential benefit in a broad range of cancers, including tumors that are not responsive to immuno-therapy or that have developed resistance to checkpoint inhibitors. ABX-001 is well suited for monotherapy, but is also well positioned to be combined with other modalities such as chemotherapy, CPIs, T-cell engangers, ADCs and cell therapy. Beyond ABX-001, Abalos is developing the next clinical candidate, that adds specific activity to the benefits offered already by ABX-001. Pre-clinical PoC for the next compound is expected in the coming 12 months.

AM-Pharma, a private clinical stage biotech company based in Utrecht, the Netherlands, is developing its proprietary recombinant human alkaline phosphatase therapeutic, ilofotase alfa as an enzyme replacement therapy administered sc for the rare disease hypophosphatasia, clinical PoC achieved, the compound can be on the market by 2030 and the market potential exceeds EURO 1B.

DelSiTech is a technology platform company specializing in long-acting formulations, dedicated to transforming the treatment landscape in the areas of metabolic disease and pain through our lead long-acting injectable assets. DelSiTech’s proprietary Silica Matrix technology platform is highly versatile and has demonstrated compatibility with a wide range of therapeutic agents, including small molecules, peptides, and large biologics. The product can be formulated to release drug over days, weeks, or even months, providing patients and caregivers with possible access to long-lasting treatment options. DelSiTech believes in collaboration. Our global partner network spans the biopharmaceutical and pharmaceutical industries, and we remain dedicated to working together to advance ultra long-acting drug delivery solutions through our Silica Matrix technology.

ErVimmune is a French preclinical biotechnology company founded in October 2019 by Prof. Stéphane Depil, an onco-hematologist and researcher at the Centre Léon Bérard and Cancer Research Center of Lyon. A spin-off from the Centre Léon Bérard, ErVimmune specializes in developing next-generation cancer vaccines and cell therapies that target ‘cold tumors’ - cancers that do not respond to current immunotherapies. The company’s innovative approach is based on identifying and selecting new sources of unconventional tumor epitopes derived from human endogenous retroviruses (HERVs). Because of their similarity to viral protein fragments recognized as foreign by the immune system, HERV-derived antigens are prime targets, shared by different tumors, for the development of cancer vaccines and T-cell based immunotherapies, especially in tumors that respond poorly to current treatments. The first indications represent two major unmet medical needs: triple-negative breast cancer (TNBC), accounting for approximately 15% of breast cancer cases worldwide and known for its aggressivity, and ovarian cancer, the deadliest cancer among women globally.

ExpreS2ion is a clinical-stage biotechnology company developing next-generation immunotherapies and vaccines based on its proprietary ExpreS2 protein expression platform, in combination with Virus-Like Particle (VLP) technology used across several pipeline assets. The company’s capabilities enable efficient production of complex antigens and their presentation in highly immunogenic formats, supporting applications across oncology and infectious diseases. ExpreS2ion’s lead clinical asset, ES2B-C001 (HER2-VLP), is a first-in-class therapeutic cancer vaccine currently in Phase I clinical development for advanced HER2-positive and HER2-low breast cancer, with dose escalation ongoing. Early clinical data indicate a favorable safety profile and induction of HER2-specific immune responses. Topline Phase Ia data are expected in the second half of 2026, with Phase Ib data anticipated by the end of 2026. Beyond its lead program, ExpreS2ion maintains a diversified pipeline and a strong track record of partnerships, having produced hundreds of recombinant proteins and VLP-based constructs for academic and industry collaborators. This platform-driven approach provides multiple opportunities for value creation through internal development, strategic collaborations, and partnering.

Fapon Biopharma develops biologics targeting cancers, autoimmune disorders, CNS diseases, and other unmet medical needs. Our platforms include FILTEN (IL-10M Fusion Protein), Bi/Tri-TCE (VHH-based), targeted LNP delivery with bi-specific antibody ligands, PROTiNb, and more. With a differentiated pipeline and end-to-end capabilities from discovery to early clinical development, we are dedicated to delivering innovative medicines that improve patient outcomes worldwide.

At Hephaistos, we are developing 3rd generation innate immune boosters with improved safety profile for intravenous use. They are designed to restore effective anti-tumor immunity in patients who don’t respond to current immunotherapies. Our novel immunotherapy strategy enables controlled activation of innate immune cells. We turn tumor-supporting macrophages in the tumor-microenvironment into cancer killers and boost dendritic cells functions, the master regulator of immunity. This subsequently activates memory tumor killing lymphocytes, driving a precise, broad, and durable immune response to overcome immune resistance, prevent relapse and even tackle metastases. Our lead drug candidate is a systemically active high-therapeutic-index TLR4 activator generated from our first-in-class proprietary engineering platform with strong patent protection. In parallel, Hephaistos is developing next-generation adjuvants that maximize long term protection of vaccines. Our differentiation lies in our ability to: • Drive precise, controlled activation of innate immunity • Reshape the tumor microenvironment to boost local anti-cancer immunity • Strengthening long-lasting T-cells response • Avoid the systemic toxicity historically associated with broad immune stimulators • Enable intravenous injection which opens the way to treating hard to access tumors and metastatic patient which all together represents 80% of the patients. This approach should be a game changer for immunotherapy and intravenous administration is the holy grail for innate immune boosters. EIKON, a US competitor, just raised 351M$ last year with an intravenous TLR7 innate immune booster. We want to be in the clinic as the third-generation TLR agonis wave accelerates and enters a new deal cycle - like ADCs did five years ago! I would also emphasize that this is a French and European breakthrough, and obviously that industrial and medical sovereignty are more important than ever.

Intragel Therapeutics has introduced a novel long-acting injectable (LAI) platform, SRGel, that allow single and safe application of drugs replacing multiple dosing for patients and reducing side effects with prolonged exposure of days to months of small molecules, peptide and biologics. SRGel is already clinically validated through phase 1 study in oncology space for patients that are unfit for systemic therapy and surgery.

In a nutshell, invIOs is a privately held biotech company focused on discovering and developing innovative cancer immunotherapies. In the field of glioblastoma, we have an ongoing collaboration with the Dana-Farber Cancer Institute, Boston, Mass. (Harvard Medical School). invIOs was founded in 2022 from a spin-off of early-stage projects from APEIRON Biologics AG, which was sold to a US pharmaceutical company in 2024. invIOs is based in Vienna, Austria.

Khondrion is a European phase-3 biopharmaceutical company developing a first-in-class, disease-modifying therapy for primary mitochondrial disease, initially targeting patients carrying the m.3243A>G mutation. This genetically defined population suffers from a chronic, progressive, multi-system disorder characterized by severe fatigue, muscle weakness, cognitive impairment, and reduced quality of life. There are currently no approved disease-modifying treatments addressing the underlying disease biology. Khondrion’s lead compound is an orally available small molecule designed to modulate pathological redox signaling and restore mitochondrial function. The program is supported by a substantial body of clinical data, including randomized controlled studies and long-term follow-up, demonstrating clinically meaningful and durable improvements across patient-relevant domains, including fatigue, physical functioning, and cognition. These domains were selected based on patient input and align with regulatory expectations in rare metabolic and neurological diseases. Following regulatory interactions in both Europe and the United States, Khondrion has initiated its pivotal Phase 3 program, with first patient in achieved and the initial wave of patients fully funded. The Phase 3 design builds on prior clinical experience and aims to support registration while preserving flexibility for geographic expansion and future lifecycle development. Khondrion is backed by a stable syndicate of family offices and patient representatives with a long-term investment horizon. The company operates with a disciplined capital allocation strategy focused on late-stage execution, regulatory readiness, and value creation toward NDA submission.

Laverock Therapeutics is powering the development of disease-responsive advanced therapies through our unique, programmable gene control technology. Our innovative platform harnesses the cell’s natural regulatory mechanisms to deliver programmable and tunable gene control through recoded miRNAs. This enables the development of highly effective medicines with enhanced precision and improved safety profiles. Utilising our platform technologies, we are working to develop the next-generation of advanced therapies, both through our own pipeline – targeting oncology and genetic medicine – and through partnerships. Laverock has a highly experienced leadership team with proven track records in biotechnology, pharma and academia and an exceptionally strong Board. Laverock has raised more than £20m seed funding to date from high-calibre investors including Calculus Capital, Eli Lilly and Company, Mercia Ventures, Maven Capital Partners, Eos Advisory, UK Innovation & Science Seed Fund, Tekfen Ventures and Norcliffe Capital.

Limula (www.limula.ch) is a Swiss company building a device as critical hospital infrastructure to make personalised cancer cell therapies scalable and accessible to patients.

Based in Oslo, Norway, Lytix Biopharma is a clinical-stage biotech company with a highly differentiated oncolytic molecule platform based on world-leading research in host-defense peptide-derived molecules. Lytix Biopharma’s lead product, ruxotemitide (formerly LTX-315), is a potent, safe and well-tolerated first-in-class oncolytic molecule representing a new approach to maintaining durable anti-cancer immunity. Lytix Biopharma has a pipeline of molecules that work across multiple cancer indications and treatment settings, both as mono- and combination therapy.

Metys Pharmaceuticals AG is pioneering next-generation treatments for neuropathic pain and cognitive impairment with our patented non-racemic dimiracetam, MP-101 — a 3:1 R-to-S enantiomer mixture that's significantly more potent than its racemic predecessor. Building on a successful Phase 2 trial in 117 patients showing safety and promising efficacy against HIV-associated pain, we've secured worldwide patents and FDA confirmation to leverage existing data for accelerated development. We're now advancing MP-101 into a Phase 2 trial to prevent oxaliplatin-induced cold sensitivity in colorectal cancer patients, with proven preclinical results across broader neuropathic and cognitive models. We seek CHF 20 million in two tranches: 1.5 million for initial cGMP production and regulatory submissions, followed by 18.5 million post-approval for the trial. This positions us for rapid value creation in a multi-billion-dollar market. Let's partner to bring this breakthrough to patients—I'm Mike Scherz, founder and CEO.

O11 Biomedical is a pharmaceutical startup from RWTH Aachen University developing a breakthrough oral therapy for hypercapnia in severe COPD. Its patented CO₂-absorbing microparticles enable effective CO₂ removal via the gut, offering a patient-friendly alternative to non-invasive ventilation with superb effectivity.

PhoreMost is a Cambridge UK-based biotechnology company dedicated to turning scientific breakthroughs into life-changing cancer therapies. The company has a number of disclosed alliances with partners, including Roche and Boehringer Ingelheim. PMC-001 | Phase-1 ready asset positioned for solid tumours including brain metastasis. PMC-002 | Novel synthetic lethal target for treatment of HPV+ cancers PMC-003 | Degrader driven by novel ligase to overcome limitations of pan-BRD4i TPD Platform | ‘Beyond Cereblon’ chemical ligase platform(s) for protein-of-interest degradation and pipeline expansion.

StemSight is a pre-clinical stage biopharma company developing proprietary hypoimmune, allogeneic cell-based therapies derived from human induced pluripotent stem cells (iPSCs) to treat blindness. Our technology platform using proprietary differentiation methods and biomaterial carriers have spun out two different products. We showcase our technology in the rare disease limbal stem cell deficiency, a high-reimbursement-potential unmet need, while looking to expand the platform to more major indications.

SUPERBRANCHE is a nanomedicine company specializing in imaging, therapy monitoring and theranostics. It has a technological platform for the development of new generation nanomaterials.

Akasi Pharma is a Copenhagen-based therapeutics company developing a selective somatostatin receptor 4 (SSTR4) small peptide agonist for peripheral neuropathic pain, initially diabetic peripheral neuropathic pain. The company’s strategy is to translate a clinically validated pain target into a peripherally acting therapy with a safety-focused profile suitable for chronic use. A key differentiator is Akasi’s peptide-based approach and long-acting injectable design. In pain, many programs are small molecules, while peptides can enable high receptor selectivity and deliberate tuning of exposure and duration. Akasi has generated long-acting peptide leads and is advancing them through lead optimization to support infrequent dosing and sustained peripheral target engagement. The long-acting injectable profile is also intended to support improved long-term usability and to reduce gastrointestinal side effects by avoiding frequent oral dosing and limiting systemic exposure peaks, and the peptide modality avoids CNS penetration seen be many competitors. The program also emphasizes drug–drug interaction risk management, including evidence of favorable behavior on renal transporters relevant to metformin elimination, which is important in diabetic populations where polypharmacy is common.

ELARIS is a biotechnology company developing next-generation bacterial vaccines that preserve health and quality of life, particularly in aging populations. The company’s lead program is a highly differentiated vaccine against Clostridioides difficile (C. difficile), a severe hospital-acquired diarrheal infection that disproportionately affects elderly and vulnerable patients. By shifting the focus from treatment to prevention, ELARIS aims to reduce hospitalizations, antibiotic use, and the growing burden of antimicrobial resistance.

Epitome Therapeutics is developing a new therapeutic modality for precise and durable activation of endogenous genes through epigenetic programming. The company focuses on genetic and metabolic diseases, with initial programs in liver-directed indications. Epitome is led by an experienced management team with a strong track record in building and advancing innovative biotechnology companies.

Hemastatx is committed to bringing scientific innovation to patients with severe and underserved bleeding disorders. A spin-off from KU Leuven, Hemastatx has secured initial funding from an international syndicate led by BaseLaunch. Hemastatx's lead program, HMX-001, is a first-in-class antibody therapy designed to treat severe bleeding episodes in patients with disorders related to von Willebrand factor (VWF), including VWD type 2A and acquired von Willebrand Syndrome. Unlike current treatments that manage symptoms, HMX-001 directly targets the root cause of bleeding by inhibiting ADAMTS13, an enzyme responsible for excessive VWF degradation. This mechanism restores critical clotting function in patients with limited therapeutic options. Preclinical studies with HMX-001 demonstrate clear target engagement and preservation of HMW VWF multimers across relevant disease models and ex vivo assays. This robust dataset is the base of a broad intellectual property portfolio.

Meddenovo Drug Design is a Lyon-based drug design company developing cyclic peptide therapeutics for oncology and radiopharmaceuticals. The company was founded to address a fundamental bottleneck in early drug discovery: the difficulty of generating viable lead candidates for complex and hard-to-drug targets when no starting molecule exists. Meddenovo is incubated at Bayer Life Hub, benefiting from a strong innovation ecosystem and close interaction with industry expertise. The company has raised €1.7M in total funding, combining equity and non-dilutive support. Meddenovo is also an i-Lab laureate, a highly selective French government deep-tech program that recognizes startups with high innovation potential, and significant growth prospects. Through this program, Meddenovo receives direct public funding and benefits from long-term institutional trust, reflecting national-level confidence in its technology and team. After finalizing its pre-seed round in 2025, Meddenovo successfully achieved its planned development and business milestones. In less than two years, the company advanced its technology into a robust, ready-to-use AI platform dedicated to cyclic peptide drug design, which is now actively applied in drug discovery projects. Meddenovo’s proprietary AI/ML-powered platform enables the de novo design and optimization of cyclic peptide drug candidates. Unlike traditional approaches that depend on prior experimental data or limited libraries, the platform allows rational exploration of a large and biologically relevant chemical space while prioritizing drug-like properties, target engagement, and functionalization potential. This makes the technology particularly well suited for oncology applications, including targeted radiopharmaceuticals. Meddenovo advances its own internal pipeline while forming strategic partnerships with pharmaceutical companies. The company has already entered into a partnership agreement with a large pharmaceutical group, providing early industrial validation of its scientific approach and technology. Meddenovo is currently preparing its seed financing round, planned to be finalized in 2026, to further advance its cyclic peptide pipeline and expand strategic partnerships in oncology.

Meliodays is a young pharmaceutical company developing MelioOne: a first-in-class intrauterine device for menstrual pain relief through a local anti-inflammatory therapy. With its novel controlled-release technology, which relies on pre-approved materials and a well-known drug with an established safety profile, Meliodays aims to increase efficacy while reducing systemic side effects often associated with currently approved treatments. This intrauterine platform has the potential to treat additional indications such as endometriosis, adenomyosis, and uterine fibroids, and to support improved outcomes in assisted reproductive technologies. Our functional prototype is currently advancing through nonclinical development.

Nerai engineers highly specific, clinically minded CRISPR editors using AI and high-throughput evolution. Designed for reusability, our editors can power multiple indications by changing only the guide RNA. With lead program validated in vivo (rare metabolic disease), we're now raising a Seed to broaden the pipeline into the ocular field.

OncoNex-Remunity Inc. is a clinical-stage company founded in 2024 that is based in Houston, Texas, and Paris, France; the company is currently incorporating an affiliate in Hong-Kong. A project supported by NxR Biotechnologies GmbH (Basel, Switzerland), OncoNex-Remunity is advancing the development of two best-in-class big pharma legacy Phase I/II assets. Its pre-clinical portfolio is comprised of a late preclinical first-in-class big pharma-legacy TCE and a proprietary platform technology patented in 2025 to develop immunostimulatory ADCs, including dual payload ones to selectively destroy T-regs in the tumour micro-environment. OncoNex-Remunity is formally supported by Paris Saclay Cancer Cluster and incubated in France in the Servier/BioLabs incubator, and in the USA by Portal Innovations and TMCi. The company has access to world-renowned KOLs who notably have been instrumental in the recent approvals of leading cancer therapeutics for several big pharmas.

First-in-Class STAT5 Oligomerization Inhibitors - Overcoming Drug Resistance in FLT3+ Acute Myeloid Leukemia.

Tandem Therapeutics is a mechanomedicine company pioneering a new class of disease-modifying antifibrotics through mechano-targeted Peptide-Drug Conjugates (PDCs). Our proprietary peptides turn the fibrotic microenvironment, long considered a barrier to therapy and a key disease driver, into a selective delivery system, enabling potent and safe treatments for progressive fibrosis. The company’s lead program targets progressive pulmonary fibrosis, with a modular platform expandable across fibrotic organs.

Moving beyond approved Ras-MAPK pathway inhibition, TheraPPI targets pathway dysregulation through a founder-identified PPI drug target. Robust preclinical data support the potential for superior and more durable therapeutic efficacy against cancer.

Tuari Therapeutics aims to develop groundbreaking medicines by targeting difficult-to-drug GTPases which are dysregulated in life-threatening diseases.

Ultimate Medicine (UM) is a Swiss preclinical biotech focused on maximizing the healthspan of patients with Alzheimer's disease and other dementias. The company is pioneering a class of small molecules targeting elevated levels of a novel toxic metabolite that disrupts critical neuronal functions and accelerates disease progression. The company’s lead program is an oral small-molecule inhibitor designed to block metabolite synthesis, thereby reducing systemic and brain exposure through natural clearance mechanisms.

Vectiopep: Unlocking T-Cell Potency via Precision mRNA Delivery Vectiopep is a preclinical-stage biotech pioneering a next-generation mRNA delivery platform designed to overcome the "liver-sink" limitations of current technologies. Our mission is to transform the treatment landscape for cold tumors, specifically Micro-satellite Stable Colorectal Cancer (MSS CRC), where standard immunotherapies often fail. The Technology: - Leveraging our proprietary, patented peptide-based mRNA vector, Vectiopep enables a fundamental shift in biodistribution. We achieve >99% selective delivery to the lymphoid organs, with negligible off-target liver accumulation. - This precision triggers an unprecedented immune response, driving 10x stronger antigen-specific T-cell activation than industry-standard lipid nanoparticle (LNP) benchmarks, significantly widening the therapeutic window. Pipeline & Status: While our lead program focuses on MSS CRC, our platform’s superior biodistribution has broad-spectrum applicability, including in vivo CAR-T and high-potency preventive vaccination for complex pathogens. With our core patent granted and €1.2M in recent funding, we have finalized Lead Candidate selection and are now advancing toward Lead Compound selection in H2 2026.

Duo Oncology is rebuilding the foundation of cancer medicine with single infusion, prodrugs designed to replace multi-agent chemotherapy regimens in solid tumors. Its lead program, DUO-207, consolidates commonly co-administered cytotoxic agents into a single, tumor-targeted prodrug designed to improve intratumoral exposure while reducing systemic toxicity. The program is supported by completed IND-enabling studies, orphan drug designations, and strong preclinical benchmarks versus standard of care. Duo is advancing toward first-in-human studies with a capital-efficient clinical strategy focused on rapid clinical validation and strategic partnering, supported by both strategic pharmaceutical investment and non-dilutive funding.